Industrials · Aerospace & Defense · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-02) | $199.25 · market cap ~$268B |
| Synthos scores (0–10) | Downside Risk 5 · Growth Quality 6 · Exponential Potential 3 |
| Synthos fair value (base case) | ~$205 → +3% · full range $140 (bear) – $250 (bull) |
| Street consensus | $224 (high $240 / low $204; 18 Buy · 8 Hold · 0 Sell) — context, not our anchor |
| Valuation | 37× trailing EPS · 29× FY26E · 26× FY27E · 20× FY30E · EV/S 3.3× · EV/EBITDA 19.5× |
| Exponential Potential | 3/10 · Low — ~6% revenue CAGR at a $268B cap; a steady prime, not a multibagger |
| Technicals | Uptrend — $199, −6% off 52-wk high, above 50/200-DMA, RSI 68, +38% 12-mo (SPY +21%) |
| Conviction | Low — only 2 KB voices (Odd Lots, Compound & Friends), both bullish, no cautionary voice; call rests on fundamentals + quant |
| Position sizing | Core-defensive ballast, ~2–3% satellite weight (income + defense-cycle exposure) |
| Next catalyst | 2026-07-23 Q2'26 earnings (Street EPS $1.66) |
| Single biggest risk | Execution/quality on Pratt & Whitney (GTF powder-metal recall history) and rich multiple leaving no room for a stumble |
One-line thesis. RTX is a top-tier defense/aerospace prime riding a record $271B backlog and a genuine post-GTF earnings recovery (FY25 revenue +9.7% to $88.6B, adjusted EPS climbing double-digits), but at 37× trailing / 29× forward with only ~6% forward revenue growth, the multiple already prices the recovery — so we like the business, not the entry, and land near the current price.
RTX (formerly Raytheon Technologies) builds jet engines (Pratt & Whitney), cockpit and cabin systems (Collins Aerospace), and missiles and air-defense systems like Patriot (Raytheon). Half its work is for airlines and planemakers, half for militaries. It has a mountain of orders already signed — about $271 billion — so the next several years of revenue are unusually visible.
The catch: the stock is not cheap. You're paying about 37 dollars for each dollar of last year's profit, and the business only grows sales in the mid-single digits. Great company, full price. Our verdict is Buy — Tactical: a solid, steady holding for income and defense exposure, but don't expect fireworks and don't overpay chasing it.
Here's what our three scores mean in everyday terms:
The one big worry: Pratt & Whitney had a costly engine-powder defect a couple of years back that cost billions. Any repeat of that kind of manufacturing or quality problem, at this rich price, would sting.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 68.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = RTX · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
“Raytheon announced it will ramp five munitions lines, with more increases to come, as the Pentagon pushes primes to maximize output.”
“21st-century war is fought with cheap one-way kamikaze drones that must be constantly replaced; JEDI ETF captures the munitions/drone basket.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
RTX Corporation (NYSE: RTX) is a ~$268B-market-cap aerospace-and-defense prime, formed from the 2020 merger of Raytheon and United Technologies' aerospace units and renamed from Raytheon Technologies to RTX in July 2023. It runs three segments, and uniquely spans both the commercial aerospace cycle and the defense-spending cycle — a diversification most pure-play peers lack. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
The two engines of the story are (a) the commercial aftermarket recovery — airlines flying more, engines needing spares and overhauls at high margin — and (b) the defense munitions ramp, where the Pentagon is pushing primes like Raytheon to maximize output (see §2). Backlog stood at $271B at Q1'26 ($162B commercial, $109B defense) — several years of visible revenue.
Honest breadth caveat up front: RTX has only 2 claims in the Synthos KB, both bullish, and no dedicated cautionary voice. This is not a high-conviction expert name like our flagship compounders — the verdict here is fundamentals- and quant-driven, with the KB used only as supporting color. Both threads point at the same catalyst:
odd_lots-pYz8vkMXAHM:3c70fe34c0, bullish, conviction 70, dated 2026-03-16): "Raytheon announced it will ramp five munitions lines, with more increases to come, as the Pentagon pushes primes to maximize output." This is the concrete, RTX-specific catalyst — and it shows up in the numbers (Raytheon Q1'26 operating profit +25% on Patriot/GEM-T and naval-munitions volume).compound_and_friends-I601uZxpNoM:d1f41f3485, bullish, conviction 55, dated 2026-03-03): "21st-century war is fought with cheap one-way kamikaze drones that must be constantly replaced; [the] JEDI ETF captures the munitions/drone basket." This is a thematic tailwind for the whole defense-munitions complex, of which Raytheon is a core holding — not an RTX-specific stock call.Honest composite note. Two bullish voices, no bear in the file, and the more RTX-specific one (Odd Lots) is a production-ramp observation rather than a valuation-aware buy recommendation. We treat the KB as confirming the operational tailwind, not as conviction breadth. The rating below leans on the fundamentals, the balance sheet, and the valuation — where we are more cautious than the two bulls.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.31 and a $271B backlog make revenue unusually visible, but 37× trailing / 29× forward and net-debt/EBITDA 2.1× leave little cushion, and Pratt's GTF recall history is a real tail. |
| Growth Quality | 6 · Good | ~14% forward EPS CAGR (FY25→FY30E) on margin recovery and buybacks, but only ~6% revenue CAGR; durable moat, steady — not fast — compounding. |
| Exponential Potential | 3 · Low | A $268B mega-cap prime growing revenue mid-single-digits. The munitions ramp is genuine but incremental; law of large numbers caps the multibagger. A small accelerating defense name would score far higher. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Aftermarket stays hot, munitions ramp accelerates, no new Pratt charge; FY27E adjusted EPS beats to ~$8.30 (vs ~$7.62 cons); multiple holds premium ~30×. | ~$250 (+25%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$7.62; a steady high-quality prime earns ~27× on visible backlog. | ~$205 (+3%) |
| Bear | New GTF/quality charge, aftermarket softens, or defense-budget/CR friction; FY27E EPS misses to ~$7.00 and multiple de-rates to ~20×. | ~$140 (−30%) |
Synthos fair value = the base case, ~$205 (+3%), with the full $140–$250 span as the honest range. Our base sits below the Street's $224 consensus: we think the recovery is largely priced, and at 29× forward the risk/reward is more balanced than the sell-side's 18-Buy/8-Hold posture implies. Our bull essentially is the Street target; our bear takes the GTF-repeat and budget-friction tails seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). RTX is a durable compounder with limited exponential character:
Exponential Potential: Low (3/10). Own RTX for durable ~14% earnings compounding plus dividend, not for a fast multibagger. The munitions ramp (§2) is real and helps, but it moves a $268B ship incrementally. This honest framing is why RTX sits in the satellite/ballast sleeve, not the exponential tier.
RTX is not cheap on any trailing lens (37× GAAP EPS, 3.3× sales, 19.5× EV/EBITDA). The bull's defense is the same as most quality industrials: EPS grows faster than sales as margins recover and buybacks shrink the count, so the forward multiple compresses — 29× (FY26E) → 26× (FY27E) → 20× (FY30E) on consensus EPS, even at a flat price. On adjusted EPS (management's ~$6.80 FY26 guide) the forward P/E is a more digestible ~29×, still a premium to the defense-prime peer group. A reverse read: at ~$199 the market is paying up for backlog visibility and margin recovery, leaving little margin for a Pratt stumble. Street targets (context): consensus $224, high $240, low $204 — notably, even the Street low is above today's price, reflecting a constructive sell-side. Our base ~$205 is deliberately below consensus because we think the recovery is largely in the price. Not a value buy; a quality-prime-at-a-full-price buy.
RTX's moat is a classic defense/aerospace triple: (1) entrenched platform positions — once your engine or radar is on an aircraft or a Patriot battery, you own decades of high-margin aftermarket and spares; (2) scale + certification barriers — the capital, IP, and regulatory qualification to build jet engines or air-defense systems are close to insurmountable for new entrants; (3) backlog visibility — $271B of signed orders. The commercial/defense diversification is itself a moat: when the airline cycle sags, defense cushions, and vice-versa. The offsetting weakness is that this is a low-margin, capital-intensive, program-execution business where a single quality escape (the GTF powder-metal issue) can cost billions.
Peer set (market cap): GE Aerospace $394B (the premium comp, pure-play engines), Caterpillar $444B (industrial), Eaton $155B, Lockheed Martin $126B, General Dynamics $101B, Northrop Grumman $78B, TransDigm $75B, L3Harris $56B, Leonardo DRS $12B, Boeing $179B. Against the defense primes RTX offers the broadest commercial+defense mix; against GE it trades at a lower multiple but with lower margins and a messier recent execution record.
odd_lots-pYz8vkMXAHM:3c70fe34c0) — watch Raytheon backlog conversion and margin.Thesis tripwires (what would change the call): a new material GTF or program charge; commercial-aftermarket growth stalling below mid-single-digits; the FY26 adjusted-EPS guide being cut; or net-debt/EBITDA rising back above ~2.5×.
Buy — Tactical. RTX is a high-quality, well-diversified defense/aerospace prime with a record $271B backlog, a genuine post-GTF margin recovery (FY25 revenue +9.7%, FCF ~$7.9B), a raised FY26 management guide, and a real Pentagon-driven munitions tailwind that our two KB voices flag. But at 37× trailing / 29× forward on only ~6% revenue growth, the recovery is largely priced, our base fair value (~$205) sits just above the current $199 and below the $224 Street consensus, and the expert breadth is thin. That combination is a hold-quality business at a full price — own it for ballast and defense-cycle exposure, but don't chase it.
claim_ids (cited inline). Fabricated conviction is structurally impossible (claim-ID reconciliation). This is a low-breadth name; the verdict is fundamentals- and quant-driven, not conviction-driven.